Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 15, 2003

View Archived Issues

New therapeutic target for type 2 diabetes: beta-cell apoptosis

Spotlight on PPAR agonists in development for diabetes mellitus

Spotlight on contraceptive research

New beta3-adrenoceptor agonists for urinary incontinence and other uses

Potassium channel-modulating series described by 4SC researchers

Selective progesterone receptor modulators prepared and tested at Schering AG

Wyeth presents new estrogenic agents with potential in menopause, endometriosis, etc.

Medinox patent covers novel NSAID prodrugs with improved safety profile

Bayer presents new p38 kinase inhibitors for COPD therapy

Seroquel approved in Europe for bipolar mania

Oral dosing of AVI-4557 tested in phase I study

Betaseron prefilled diluent syringe receives FDA approval

IPM grant to advance cyanovirin-N development

Bristol-Myers Squibb and Corgentech to jointly develop E2F decoy

Independent data support use of M6G for postoperative pain

Dual-acting anthrax vaccine designed by Boston-based team

ChemoCentryx awarded grant to develop chemokine-based immunomodulators

Wyeth advances NSP-989 into phase II

New data supports Cialis for ED

Metabolic licenses analgesic compound discovered at university

Preliminary observations from European trials of Hynic-Annexin V product

PEG-Intron Redipen approved by FDA

VaxGen enters license agreement with USAMRIID for vaccine technology

Selective erbB2 kinase inhibitor CP-654577 inhibits growth of human breast cancer

Flatfish-derived antimicrobial peptide discovered using genomic approach

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...